| Name | Title | Contact Details |
|---|
Equip gives families lasting recovery from eating disorders through dedicated virtual care teams and gold-standard treatment delivered at home.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.
Premier Diagnostic Health Services Inc. (“Premier”, “PDH” or the “Company”) is a Canadian corporation with its head office in Burnaby, British Columbia. PDH designs, finances, builds and operates free standing diagnostic imaging centres with no outside affiliation in Canada, and joint venture, diagnostic imaging centres in China with local hospitals. PDH specializes in PET/CT and MRI scanning for the detection and evaluation of cancer, heart disease and neurological disorders
TAMI North America is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aria Medical is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.